Home » Newsletters » BioWorld Science

BioWorld Science

April 10, 2014

View Archived Issues

Phase II interim results show improvements in infantile hypophosphatasia with asfotase alfa

GlaxoSmithKline patents novel RIP-2 inhibitors

Sideromics completes pre-IND meeting with FDA for siderocillin

First-in-human results presented for CO-1686 in EGFR-mutant NSCLC

Phase IIb results presented for bococizumab for the treatment of hypercholesterolemia

Roche discloses novel TaR-1 ligands

Bristol-Myers Squibb patents new endothelial lipase inhibitors

ERYTECH adds new product candidate to development pipeline

Kainos Medicine discloses new adenosine A3 receptor agonists

Companies simultaneously file NDAs for vemurafenib and companion diagnostic in Japan

French team presents novel V2 receptor antagonist peptides

Spero Therapeutics to develop approach for drug-resistant bacterial infections

Myriad Genetics submits premarket approval application to FDA for BRACAnalysis

Cancer Research Technologies and Teva collaboration yields novel aPKC inhibition

BLU-9931 shows antitumor activity in vitro and in in vivo HCC models with aberrant FGF-19

Hetlioz available in U.S. for non-24-hour sleep-wake disorder

Oricula Therapeutics secures intellectual property and funding to prevent hearing loss

FDA places clinical hold on Halozyme's phase II trial of PEGPH-20 for pancreatic cancer

GE Healthcare Japan enters collaboration with Nihon Medi-Physics for Abeta-imaging product

Aegerion Pharmaceuticals begins phase III trial of lomitapide in Japan

VenatoRx receives NIH grant for biodefense work

PeptiDream develops anti-influenza macrocyclic peptide therapeutic

Alkermes reports topline results from a pivotal phase III study of aripiprazole lauroxil

Pfizer describes activity of oncolytic Trop-2 antibody-drug conjugate

Pharmacyclics files supplemental NDA in U.S. for Imbruvica

Domainex compounds show activity in models of inflammation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...